Decision: Favourable

Decisions Table

Study Title:

A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG- 3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA

  • NREC Code:

    22-NREC-CT-092

  • Decision:

    Favourable

  • Meeting Date:

    11/05/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Professor John Crown

  • PI Institution:

    SVUH

  • Sponsor:

    Regeneron Pharmaceuticals, Inc.

Scroll to Top